secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001005286-24-000036
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore appoints Paul Josephs as CEO; concludes strategic review, remains standalone
--------------------------------------------------------------------------------

- Paul Josephs becomes President & CEO effective May 20, 2024, succeeding James Hall, who retires after 30+ years.
- Strategic review with 75+ buyers concluded; Board unanimously chose standalone execution.
- Josephs receives $550k base salary, 525k RSU (vest over 5 yrs), up to 1.5M PSU shares tied to stock price.
- Hall separation: $750k severance over 12 months, full equity vesting, COBRA premiums for 12 months.
- Craig Barbarosh not standing for reelection; Katrina Houde to become Board Chair at annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/lndc-20240320.htm
  HTML page:      https://secwatch.observer/filing/0001005286-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer